Chemotherapy combined with bevacizumab for the treatment of advanced lung adenocarcinoma cancer harboring EGFR‐ANXA2, EGFR‐RAD51, ATR and BRCA2 mutations: A case report

Here, we report a case of a 36‐year‐old female patient with metastatic non‐small cell lung cancer (NSCLC) harboring EGFR‐ANXA2 and EGFR‐RAD51 double fusion mutations with BRCA2 (nonsense mutation of exon 11) and ATR mutations (Exon 44 variable shear mutation) identified by next generation sequencing...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Rui Zhong, Hui Li, Yanling Liu, Shuang Zhang, Jingjing Liu, Zhicheng Huang, Ying Cheng
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2020-02-01
coleção:	Thoracic Cancer
Assuntos:	Bevacizumab chemotherapy EGFR fusion NGS NSCLC
Acesso em linha:	https://doi.org/10.1111/1759-7714.13286
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!